A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Inclusion Criteria: * 1\. Ability to provide and document informed consent and willing and able to comply with all study procedures. * Participants diagnosed with advanced solid tumors including but not limited to metastatic castration-resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer and renal cell carcinoma. * Participants have received approved therapies according to their diagnosis. * Participants must have an available tumor tissue sample. A fresh tumor biopsy may be performed if no archival sample is available. * Eastern Cooperative Oncology Group performance status of less than or equal to 2. * Life expectancy of at least 12 weeks. * Evidence of measurable tumor for evaluation * Acceptable end organ function according to laboratory results. * Patients must agree to use highly-effective contraception during the study, and not donate sperm or ova. Exclusion Criteria: * Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures. * Another malignancy that required treatment within the past 2 years. Participants who have had curative therapy for non-melanomatous skin cancer, localized prostate cancer (Gleason score \< 6), or carcinoma in situ are eligible for the study. * Active viral, bacterial, or fungal infection requiring systemic treatment within 1 week of initiation of study drug. Participants are eligible after SARS CoV…